5332592025-10-012025-12-315332592025-12-315332592025-04-012025-12-315332592025-10-012025-12-31in-capmkt:OtherExpenses1Member5332592025-04-012025-12-31in-capmkt:OtherExpenses1Member5332592025-10-012025-12-31in-capmkt:ReportableSegments1Member5332592025-10-012025-12-31in-capmkt:ReportableSegments2Member5332592025-04-012025-12-31in-capmkt:ReportableSegments1Member5332592025-04-012025-12-31in-capmkt:ReportableSegments2Member5332592025-10-012025-12-31in-capmkt:ReportableSegments1Member5332592025-10-012025-12-31in-capmkt:ReportableSegments2Member5332592025-04-012025-12-31in-capmkt:ReportableSegments1Member5332592025-04-012025-12-31in-capmkt:ReportableSegments2Member5332592025-10-012025-12-31in-capmkt:ReportableSegments1Member5332592025-12-31in-capmkt:ReportableSegments1Member5332592025-10-012025-12-31in-capmkt:ReportableSegments2Member5332592025-12-31in-capmkt:ReportableSegments2Member5332592025-10-012025-12-31in-capmkt:ReportableSegments1Member5332592025-12-31in-capmkt:ReportableSegments1Member5332592025-10-012025-12-31in-capmkt:ReportableSegments2Member5332592025-12-31in-capmkt:ReportableSegments2Member5332592025-10-012025-12-31ItemsThatWillNotBeReclassifiedToProfitAndLoss15332592025-04-012025-12-31ItemsThatWillNotBeReclassifiedToProfitAndLoss1iso4217:INRiso4217:INRxbrli:shares533259SASTASUNDRNOTLISTEDINE019J01013SASTASUNDAR VENTURES LIMITEDMain BoardEquity2025-04-012026-03-312026-02-062026-01-29INRLakhsQuarterlyThird quarterMulti segment2026-02-0615:30:002026-02-0616:30:00Not applicable2025-10-012025-12-31UnauditedConsolidated2005000137000004219700003400445000125860003457370000136163000359353300015000003258298000-107660000217158000169600021685000000019166900035843460009187000091870001477000402300055000003687000000036870001424000511100011297000-761000012302000-7191000318105000100.350.35000.350.351. The above Unaudited Consolidated Financial Results for the quarter and nine month ended December 31, 2025 have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their respective meetings held on Febraury 06, 2026. The Limited Review for the quarter and nine month ended December 31, 2025 has been carried out by the Statutory Auditors, as required under Regulation 33 of SEBI (LODR) Regulation, 2015. <BR> <BR> 2. The Group has identified the following segments : <BR> <BR> a) Financial Services - consists mainly of financing of loans and investment in shares and securities, financial consultancy, professional fees, wealth management, financial planning, distribution and related services. <BR> <BR> b) Healthcare Network - includes activities for pathology, food processing and marketing of healthcare and OTC products through e-commerce portal and diagnostic services which consist of pathological / radiological investigations. <BR> <BR> 3. Exceptional items represent the gain/ (loss) on following transaction/ event: <BR> <BR> a) During the previous year, the management of one of the step down subsidiary, Genu Path Labs Limited, has evaluated its business operation and Property, Plant & Equipment has been impaired. Accordingly the company has accounted for an impairment loss of Rs 72.37 Lakhs and disclosed the same as Exceptional items in the consolidated financial result for the year ended March 31, 2025 and nine month ended December 31, 2024. During the current year, following a further evaluation and reassessment, an additional impariment loss of Rs. 16.61 Lakhs was recognized as an Exceptional items in accordance with Ind AS 36 for the nine month ended December 31, 2025. <BR> <BR> b) During the Financial Year 2022-23, subsidiaries of the Company had expensed Rs. 796.45 Lakhs under the heading “Exceptional Item”. During the previous year, Sastasundar Healthbuddy Limited, subsidiary of the Company has now recovered Rs. 128.00 Lakhs against the aforesaid amount which has been booked as income in the consolidated financial result for the year ended March 31, 2025 under the heading “exceptional item” including Rs. 100.00 Lakhs for the nine month ended December 31, 2024. <BR> <BR> c) During the previous year, the subsidiary of the company, Sastasundar Healthbuddy Limited, has liquidated its investment held in the form of 0.01% Non-Cumulative Compulsory Convertible Preference share and Equity shares in Flipkart Health Limited on October 29, 2024 as per Share Purchase Agreement dated October 28, 2024 and received a consideration of Rs. 9,717.29 Lakhs in aggregate. <BR> <BR> This has resultant loss of Rs 19,118.54 Lakhs has been booked as exceptional items in the consolidated financial result for the year ended March 31, 2025 and nine month ended December 31, 2024 including Rs. 223.32 Lakhs of earlier quarter December, 2024. <BR> <BR> 4. The shareholders of Sastasundar Healthbuddy Limited ("SHBL"), a material subsidiary of Sastasundar Ventures Limited ("the company"), in its Extra-Ordinary General Meeting held on September 30, 2025 have approved the buy-back of not exceeding 20,27,534 (Twenty Lakh Twenty Seven Thousand Five Hundred Thirty Four) fully paid-up equity shares (representing 8.55% of the total number of shares in the paid up equity share capital of SHBL) of Rs. 10/- each, at a price of around Rs. 493.21/- (Rupees Four Hundred Ninety Three and Twenty One paise) per share aggregating to a consideration not exceeding Rs. 10,000.00 Lakhs. <BR> <BR> Pursuant to the said Buy Back offer, SHBL has accepted 20,27,534 equity shares tendered by Mitsubishi Corporation on November 11, 2025 and SHBL had paid the consideration of Rs. 10,000.00 Lakhs within the statutory time line. <BR> <BR> Consequently, the Company's shareholding in SHBL has increased from 72.14% to 78.89%. <BR> <BR> 5. During the year ended March 31, 2025, the subsidiary of the Company, Sastasundar Healthbuddy Limited, has entered into an agreement to dispose of its subsidiary, Happymate Foods Limited, and accordingly classified the investment in the said entity as Asset Held for Sale in accordance with Ind AS 105 – Non-current Assets Held for Sale and Discontinued Operations. <BR> <BR> On May 30, 2025, the sale of Happymate Foods Limited was completed, and the entity ceased to be a subsidiary of Sastasundar Healthbuddy Limited with effect from that date. <BR> <BR> 6. During the previous year, the subsidiary of the company, Sastasundar Healthbuddy Limited, has liquidated its investment in Associate Company i.e. Flipkart Health Limited on October 29, 2024. Share of Profit/ (Loss) from an associate company has been consolidated till October 29, 2024. <BR> <BR> 7. Genu Path Labs Limited, step- down subsidiary of the company, commenced its operations in the diagnostics and healthcare services segment in 2018 with a vision to establish itself as a trusted brand. Since inception, the company has undertaken several initiatives to develop its service network and physical presence. However, these efforts have not yielded the expected outcomes, resulting in operational losses. Additionally, Sastasundar Healthbuddy Limited, parent company of the Genu Path Labs Limited has assured its continued financial support to implement the revised strategies aimed at reviving and strengthening the business. <BR> <BR> 8. Genu Path Labs Limited, a step-down subsidiary, has filed a petition on April 30, 2025, with the Hon’ble National Company Law Tribunal (NCLT), Kolkata Bench, seeking approval for the reduction of share capital under Section 66 of the Companies Act, 2013. <BR> <BR> Pursuant to the Scheme of Arrangement submitted to the NCLT, it is proposed that the face value of each equity share be reduced from Rs. 10.00 (Rupees Ten) to Rs. 1.00 (Rupee One) per share. <BR> <BR> The effect of the said scheme in share capital, securities premium, and retained earnings before and after the proposed reduction is as under: <BR> <BR> Particulars Pre Reduction Proposed Reduction Post Reduction <BR> <BR> Share Capital 1,975.00 -1,777.50 197.50 <BR> Securities Premium 1,975.00 -1,975.00 - <BR> Retained Earnings -3,892.75 3,752.50 -140.25 <BR> <BR> 9. The figures for the quarter ended December 31, 2025 are the balancing figures between unaudited figures for the nine month ended December 31, 2025 and unaudited figures for the half yearly ended September 30, 2025. <BR> <BR> 10. Previous Period/ Year figures have been re-grouped / re-classified wherever necessary.2025-04-012025-12-31UnauditedConsolidated601800087480000016222000009243535000343370009454858000445112000989997000069770008753255000-18215300058927500029350004662100000005567180009773628000126342000-166100012468100063120003154000946600011521500000001152150007137000122352000123472000-8257000128538000-6186000318105000103.883.88003.883.88Other Expenses191669000Other Expenses556718000Financial Services44339000Healthcare Network3413031000Financial Services176986000Healthcare Network9277872000345737000094548580000034573700009454858000Financial Services35721000Healthcare Network-149475000Financial Services157145000Healthcare Network-434886000-113754000-27774100016960002935000-124637000-4053570009187000124681000Financial Services1218337000Healthcare Network703868200082570190004666940008723713000Financial Services62010000Healthcare Network869923000931933000240790009560120002. The Group has identified the following segments : <BR> <BR> a) Financial Services - consists mainly of financing of loans and investment in shares and securities, financial consultancy, professional fees, wealth management, financial planning, distribution and related services. <BR> <BR> b) Healthcare Network - includes activities for pathology, food processing and marketing of healthcare and OTC products through e-commerce portal and diagnostic services which consist of pathological / radiological investigations.Items that will be not reclassified subsequently to profit or loss17310001731000Items that will be not reclassified subsequently to profit or loss90020009002000307000186500014240007137000